SGM 1019

Drug Profile

SGM 1019

Latest Information Update: 16 Jan 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Unknown
  • Developer Second Genome
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action Metagenome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Inflammatory bowel diseases

Most Recent Events

  • 12 Jan 2015 Second Genome in-licenses SGM 1019 from an undisclosed biopharmaceutical partner
  • 12 Jan 2015 Phase-I clinical trials in Inflammatory bowel disease (In volunteers) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top